Enveric issues 228,690 shares for waiver of variable-rate limitation, enabling ATM facility

Enveric Biosciences, Inc.

Issued 228,690 common shares at $1.41/share to institutional investors; no proceeds to Enveric.
Investors permanently waive variable rate transaction limitation from Dec 28, 2023 inducement letters.
Waiver allows Enveric to utilize its 'at the market' offering facility with Canaccord Genuity.
Closing expected March 12, 2024; shares represent ~4.2% of outstanding (5.4M pre-offering).

item 1.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Enveric Biosciences, Inc. entered into Purchase Agreement with certain institutional investors (effective 2024-03-08).

Action: entry
Agreement: equity purchase
Counterparty: certain institutional investors
Effective: 2024-03-08

Exact text from the filing

On March 8, 2024, Enveric Biosciences, Inc., a Delaware corporation (the “Company”) entered into a series of common stock purchase agreements (the “Purchase Agreement”) for the issuance in a registered direct offering of 228,690 shares of the Company’s common stock, par value $0.01 per share (the “Shares”), to certain institutional investors.

View on SEC.gov

565 material agreements filed in the last 30 days. Browse all material agreements →

Enveric Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-24-009485

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.